Key result
New LC/MS/MS method quantifies ginsenoside Rg3 pharmacokinetics down to 0.5 ng/mL in beagle dogs.
Why the study?
A sensitive and specific LC/MS/MS method was needed to investigate the pharmacokinetics of 20(R)-ginsenoside Rg3 in dogs.
A sensitive LC/MS/MS method was successfully developed and applied for pharmacokinetic studies of 20(R)-ginsenoside Rg3 in beagle dogs.
May aid preclinical PK studies of Rg3; leaves open human translation without further validation.
A sensitive and specific liquid chromatography/tandem mass spectrometry (LC/MS/MS) method was developed for the investigation of the pharmacokinetics of 20(R)-ginsenoside Rg3 in dog. The plasma samples were pretreated by liquid-liquid extraction and analyzed using LC/MS/MS with an electrospray ionization interface. Dioscin was used as the internal standard. The method had a lower limit of quantitation of 0.5 ng/mL for Rg3 in 200 microL of plasma or 2 ng/mL in 100 microL of plasma, which offered a satisfactory sensitivity for the determination of Rg3 in plasma. The intra- and inter-day precisions were measured to be below 8% and accuracy between -1.5 and 1.4% for all quality control samples. This quantitation method was successfully applied to pharmacokinetic studies of Rg3 after both an oral and an intravenous administration to beagle dogs. No Rh2 and protopanaxadiol were detected in plasma.
No takes yet. Share an insight, caveat, or question.
Li et al. (2005) studied this question. 20(R)-ginsenoside Rg3 was evaluated on Pharmacokinetics and method validation (lower limit of quantitation, precision, accuracy). A sensitive LC/MS/MS method with a lower limit of quantitation of 0.5 ng/mL was successfully developed and applied to pharmacokinetic studies of 20(R)-ginsenoside Rg3 in beagle dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: